Home Microbiology Parasite inhibitor SQ109

research use only

SQ109 Parasite inhibitor

Cat.No.S1265

SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for LLC-MK2 culture-derived trypomastigotes of 50±8 nM, targets MmpL3 (mycobacterial membrane protein large 3) in Mycobacterium tuberculosis.
SQ109 Parasite inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 330.55

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 330.55 Formula

C22H38N2

 Storage (From the date of receipt) 2 years  -20°C  liquid
CAS No. 502487-67-4 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
MmpL3 [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01252108 Withdrawn
Helicobacter Pylori Infection
Sequella Inc.
 March 2012 Phase 2
NCT01358162 Completed
Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
 November 2010 Phase 1
NCT01218217 Completed
Tuberculosis Pulmonary
Michael Hoelscher|Sequella Inc.|European and Developing Countries Clinical Trials Partnership (EDCTP)|German Federal Ministry of Education and Research|Quintiles Inc.|CMed Technologies Inc.|PathCare|Parexel|Ludwig-Maximilians - University of Munich
 November 2010 Phase 2
NCT00866190 Completed
TB Multi-drug Resistant
National Institute of Allergy and Infectious Diseases (NIAID)
 April 2009 Phase 1
NCT01585636 Completed
Tuberculosis
Sequella Inc.|Quintiles Inc.
 September 2006 Phase 1
NCT01874314 Withdrawn
Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.